2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - La Nouvelle A-B
Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Biological Processes, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1050 Cure is Possible  among myeloma patients with more than 5 years of sustained CR and MRD negativity

Meletios-Athanasios (Thanos) C. Dimopoulos, MD, Maria Gavriatopoulou, MD2, Evangelos Eleutherakis Papaiakovou, MD3, Nikolaos Kanellias, MD, PhD4, Ioannis Ntanasis-Stathopoulos, MD5, Panagiotis Malandrakis, MD, MSc, PhD6, Foteini Theodorakakou, MD7, Eirini Solia, MD8, Magdalini Migkou9, Stavroula Giannouli10, Ilias Katsadouros, MD11, Panagiotis Boutsikos, MD12, Aikaterini Nikolopoulou, MD13, Panagiotis Tsirigotis, MD, PhD14, Aikaterini Vlachou15, Asimina Papanikolaou16, Evangelos Terpos, MD17, Efstathios Kastritis, MD18
1 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
4 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
5 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
6 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
7 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
8 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
9 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
10 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
11 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
12 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
13 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
14 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
15 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
16 Evangelismos Hospital, Athens, Greece
17 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
18 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Background: Multiple myeloma (MM) has been considered as an incurable disease; however, treatment advances over the past 25 years improved outcomes, especially rates of complete responses and longer progression free and overall survival (OS). Deep responses drive longer remissions and may lead to cure. The IMS Myeloma Cure Summit proposed that cure may be considered in patients (pts) who achieve sustained MRD negativity, remain free of detectable disease on modern imaging and laboratory assessment, and stay off therapy for at least five years, suggesting a very low likelihood of subsequent relapse. However, in the real world setting longitudinal MRD data and/or advanced functional imaging may be missing while treatment discontinuation in the era of lenalidomide maintenance is not universally applied. To provide an estimation of the cure fraction among MM pts in the real-world setting, in a cohort with mature follow-up, we evaluated the long-term outcomes of pts with long sustained CR, whether they had detectable or undetectable MRD.

Methods: The analysis included 1265 consecutive pts treated and followed in a single center (Department of Clinical Therapeutics, Athens) from 1994 to 2018 (minimum follow up for living pts ≥7 years). We focused on pts that had achieved a CR during 1st line therapy; MRD was assessed using NGF according to the Euroflow guidelines (sensitivity 2x10-6). 

Results: The median OS of the cohort was 5.5 years, median PFS to 1st line therapy was 2.6 years. The median follow-up of pts that were progression-free at 5-years was 10 years; 318 (25.1%) pts achieved CR during 1st line therapy and 204 (16.1%) were progression-free and alive at ≥5 years; among the other CR pts, 82 (6.5%) relapsed and 32 (2.5%) died without documented MM relapse in <5 years. For pts being progression-free and alive at 5 years, their PFS was 11.2 years from start of therapy (6.1 from the 5-year landmark); however, the median post-5-year PFS was 6.3 years for those in CR vs 4.8 years for pts at <CR at the 5-year landmark (HR: 0.58, 95%CI 0.42-0.80, p<0.001). For pts in CR at 5-year landmark the average annual progression or death rate was 7% (95%CI 2-12%) per year for years 6-10, and 9% (95%CI 0-20%) per year for years 11-15. Among pts at CR at 5-year landmark, 83% remained in CR at 7 and 70% at 10 years. The median estimated OS of pts at CR at 5 years was 25 years (95%CI 14-36)   (from start of therapy).

Compared to pts who failed to achieve or sustain CR for 5 years, those with ≥5 years sustained CR were younger (median age 60 vs 69 years, p<0.001), had better renal function (median eGFR 92 vs 69 ml/min/1.73 m2, p<0.001), less advanced disease (ISS-3 in 18% vs 44%, R-ISS-stage 3  in 7.5% vs 22% and R2-ISS stage 3 & 4 in 34% vs 65%, p<0.001 for all), less often low albumin (25% vs 39%, p<0.001), ECOG PS>1 (17% vs 44%, p<0.001), anemia (Hgb<10 gr/dl) (28% vs 48%, p<0.001), low platelet counts (5% vs 11%, p=0.017) or high risk cytogenetics by IMS CGS (16% vs 30%, p=0.004), were treated more often with PI+IMiDs (45.6% vs 18.5%), daratumumab-based induction (16% vs 1.5%), HDM-ASCT (68% vs 23%), consolidation (37% vs 9%, p<0.001) and maintenance therapy (74.5% vs 26.5%)(p<0.001 for all comparisons). Following treatment evolution, there was a significant increase in the fraction of pts within each calendar year of starting therapy achieving the 5-year CR landmark, with <2% before 2006, to 15.5% among pts starting therapy in 2016, and 31% in 2019 (p<0.001). These improvements paralleled the achievement of CR at the same time (increasing from ~5% to 44% in 2019) (p<0.001). In multivariate analysis attainment of sustained CR was driven by younger age, ECOG PS, era of diagnosis and cytogenetics. We then evaluated how many of the pts in sustained CR were MRD negative, and among evaluable pts (n=134), 79% were MRD negative with a PFS rate at 10 years of 94% for MRDneg (vs 39% for MRDpos, p<0.001).

Conclusion:  there is a substantial increase in the proportion of pts who achieve sustained CR over the recent years, even before wider implementation of anti-CD38-based therapies and new immunotherapies. Such pts had mostly standard risk disease and were treated with ASCT and maintenance/continuous therapies. Sustained CR for over 5 years is associated with low risk of subsequent relapse, but this is driven by undetectable MRD. Pts with sustained MRD-negative CR lasting ≥5 years may be cured. 

Meletios-Athanasios (Thanos) C. Dimopoulos, MD: Bristol Myers Squibb - Honoraria; Sanofi - Honoraria; Janssen - Honoraria; BeiGene - Honoraria; Amgen - Honoraria; Regeneron - Honoraria; Swixx BioPharma - Honoraria; GSK - Honoraria; Takeda - Honoraria; Menarini - Honoraria; AstraZeneca - Honoraria; Takeda - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Swixx BioPharma - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Menarini - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony)